ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

DWC202518

A development code.

Its studies are mostly in Diabetes Mellitus, Type 2, led by Daewoong Pharmaceutical.

Furthest: phase 3, since May 26, 20261 company-led study, 1 open or runningNext primary completion: Nov 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Daewoong Pharmaceutical11 open or runningphase 3since May 26, 2026May 26, 2026Nov 2027phase 3 · NCT07619833

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 26, 2026First study: phase 3 study in Diabetes Mellitus, Type 2First studyNCT07619833 · 510 planned · South Korea

Ahead

  1. Nov 2027Primary completion: phase 3 study in Diabetes Mellitus, Type 2NCT07619833

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07619833Diabetes Mellitus, Type 2 · South Korea3Not yet recruitingNov 2027510

How it is read

Names in the registry

  • “DWC202518”, 1 entry

Codes read as this program: DWC202518.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.